NAPSR News: Cervical Cancer Vaccine Program in England a Success, Researchers Report

WASHINGTON - April 14, 2014 - PRLog -- A sharp drop in the number of young women infected with the two strains of human papillomavirus (HPV) most likely to cause cervical cancer occurred in England after the 2008 launch of a national vaccination program there, a new study shows.

The high-risk HPV types 16 and 18 cause 70 percent to 80 percent of cervical cancers. Protection against infection from these two types is included in HPV vaccines.

The British researchers analyzed test results from more than 4,000 young women between 2010 and 2012. Before the start of the HPV vaccination program, about one in five sexually active women aged 16 to 18 had at least one of the two high-risk HPV types. That dropped to one in 15 after the vaccination program began.

The investigators also found that this age group had the highest rate of infection with the two high-risk HPV strains before the start of the immunization program, but had the highest vaccination rate and lowest infection rate once the program began.

The study was to be presented Monday at the Society for General Microbiology annual conference in Liverpool, England. Research presented at meetings should be considered preliminary until published in a peer-reviewed medical journal.

"This study provides an early indication that the national HPV immunization program is successfully reducing vaccine-type HPV infections in sexually active young women in England, and also suggests herd immunity may be benefiting non-vaccinated young women and men," David Mesher, of Public Health England, said in a society news release.

Herd immunity happens when vaccination of a large portion of a population affords some protection against infection to those in the population who are not vaccinated.

NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD. With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!- Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative(CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.